Screening for<unk>  is limited by a lack of established diagnostic criteria, although many have been proposed. Diagnostic criteria for other conditions such as sarcopenia or cachexia can be used. These syndromes can also be identified with screening questionnaires. Muscle mass and changes can be quantified on imaging studies such as CT scans or Magnetic resonance imaging (MRI). Biomarkers such as urine urea can be used to roughly estimate muscle loss during circumstances of rapid muscle loss. Other biomarkers are currently under investigation but are not used in clinical practice.
Muscle atrophy
Muscle weakness
Muscle hypertrophy
Breast atrophy
Muscle imbalance
Lipoatrophy
Tooth loss
Lumbar enlargement